Hematopoietic cell transplantation for Chediak-Higashi syndrome

M Eapen, C A DeLaat, K S Baker, M S Cairo, M J Cowan, J Kurtzberg, C G Steward, P A Veys, A H Filipovich

Research output: Contribution to journalArticle (Academic Journal)peer-review

66 Citations (Scopus)


We reviewed outcomes after allogeneic hematopoietic cell transplantation (HCT) in 35 children with Chediak-Higashi syndrome (CHS). Twenty-two patients had a history of the life-threatening accelerated phase of CHS before HCT and 11 were in accelerated phase at transplantation. Thirteen patients received their allograft from an human leukocyte antigen (HLA)-matched sibling, 10 from an alternative related donor and 12 from an unrelated donor. Eleven recipients of HLA-matched sibling donor, three recipients of alternative related donor and eight recipients of unrelated donor HCT are alive. With a median follow-up of 6.5 years, the 5-year probability of overall survival is 62%. Mortality was highest in those with accelerated phase disease at transplantation and after alternative related donor HCT. Only four of 11 patients with active disease at transplantation are alive. Seven recipients of alternative related donor HCT had active disease at transplantation and this may have influenced the poor outcome in this group. Although numbers are limited, HCT appears to be effective therapy for correcting and preventing hematologic and immunologic complications of CHS, and an unrelated donor may be a suitable alternative for patients without an HLA-matched sibling. Early referral and transplantation in remission after accelerated phase disease may improve disease-free survival.
Original languageEnglish
Pages (from-to)411-5
Number of pages5
JournalBone Marrow Transplantation
Issue number7
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Hematopoietic cell transplantation for Chediak-Higashi syndrome'. Together they form a unique fingerprint.

Cite this